Early riser specific immune cell response by delayed-type hypersensitivity in a kidney transplant patient vaccinated against COVID-19
Authors:
Open Access
- 13 December 2022
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 15 (12) , e250509
Abstract
We present a female kidney transplant patient under conventional immunosuppression therapy. Her humoral immunity study (anti-spike-specific antibodies) was negative after the initial regimen and the third dose of vaccination against COVID-19. The specific ex vivo cellular immune study against spike of SARS-CoV-2 by interferon gamma release assay (IGRA) also remained at non-response levels at different time points despite an optimal non-specific cell immune response assessment. However, the cellular immunity test by delayed-type hypersensitivity (DTH) with spike of SARS-CoV-2 was always positive since the vaccination scheme began. Only after COVID-19 infection has there been a seroconversion of the patient’s antibody tests along with IGRA positivity. The use of DTH test to measure the immune response could be a better and earlier parameter of the actual immune status that helps us to predict the immune response in real life. Hybrid immunity combining vaccine and natural infection could be a stronger stimulator of the specific global immune response.Keywords
Funding Information
- Fundación de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC 2021 Beca20A4)
This publication has 25 references indexed in Scilit:
- Impact of COVID-19 in solid organ transplant recipientsAmerican Journal of Transplantation, 2022
- Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipientsKidney International, 2021
- Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathyKidney International, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine AdministrationTransplantation, 2021
- Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across EuropeKidney International, 2020
- Validation of a commercially available SARS-CoV-2 serological immunoassayClinical Microbiology and Infection, 2020
- Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised PatientsClinical Infectious Diseases, 2010
- Decreased Antibody Response to Influenza Vaccination in Kidney Transplant Recipients: A Prospective Cohort StudyAmerican Journal of Kidney Diseases, 2009
- Vaccination of the solid organ transplant recipientTransplantation Reviews, 2008